MedTrace Logo

Determine the Effect of AZD3161,Injected Intradermally, on Quantitative Sensory Testing Variables in Normal and Ultraviolet-C (UVC) Exposed Skin in Healthy Volunteers

NCT01240148 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2011-04-12

No results posted yet for this study

Summary

The purpose of this study is to investigate the effect of AZD3161 on mechanical pain sensitivity and axon reflex flare in normal and ultraviolet C irradiated skin.

Conditions

  • Peripheral Neuropathic Pain
  • Nociceptive Pain

Interventions

DRUG

AZD3161

Single dose, intradermal injection

DRUG

Lidocaine

Single dose, intradermal injection

DRUG

AZD3161 Placebo

Sponsors & Collaborators

Principal Investigators

  • Darren Wilbraham, MD, MBBS DCPSA · Quintiles Drug Research Unit at Guy's Hospital

  • Bo Fransson · AstraZeneca R&D

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01240148 on ClinicalTrials.gov